Curis, Inc. Announces Pricing of $5.6 Million Public Offering
Rhea-AI Summary
Curis (Nasdaq: CRIS) priced a public offering with certain new and existing healthcare-focused institutional investors for 3,733,334 shares of common stock (or pre-funded warrants in lieu thereof) plus accompanying warrants to purchase up to 3,733,334 shares at a combined price of $1.50 per share and warrant, or $1.49 per pre-funded warrant and warrant.
The common warrants have a $1.75 exercise price, are exercisable immediately and expire five years from issuance; pre-funded warrants have a $0.01 exercise price and are exercisable immediately until fully exercised. Curis expects gross proceeds of about $5.6 million, before fees and expenses, to fund research and development, working capital and general corporate purposes. Closing is expected around August 14, 2026, subject to customary conditions.
Positive
- Gross offering proceeds expected of approximately $5.6 million
- Proceeds designated to fund research and development and corporate needs
Negative
- Issuance of 3,733,334 new shares or pre-funded warrants dilutes equity
- Additional potential dilution from warrants for up to 3,733,334 shares
- Net proceeds reduced by placement agent fees and offering expenses
News Explained
The financing is priced, not closed, adds potential ownership dilution, and its gross proceeds equal 56 days of prior-quarter operating cash use.
The priced transaction is not yet closed and is expected to close on or about
The effective Form S-1 registers the offered securities for sale, but registration alone is not a completed sale; the pre-funded warrants convert into shares when exercised and carry a nominal exercise price.
On the same quarterly operating-cash-use basis, the gross proceeds equal
The next specified checkpoints are the closing on or about
Sources and calculations
- Curis Announces Pricing of $5.6 Million Public Offering (2026-08-13)
- Dilution (2026-07-17)
- Pre-funded warrant (2026-07-17)
- Form S-1 purpose (2026-07-17)
- Curis first-quarter 2026 fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $5,600,000 / ($9,001,000 / 90) = [object Object]
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $15,001,000 / ($9,001,000 / 90) = [object Object]
Market Reaction – CRIS
Following this news, CRIS has declined 10.18%, reflecting a significant negative market reaction. Our momentum scanner has triggered 17 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $1.50. Trading volume is exceptionally heavy at 431.9x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The gross proceeds from the Offering are expected to be approximately
A.G.P./Alliance Global Partners is acting as the lead placement agent and Laidlaw & Company (
The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-298203) filed on August 10, 2026 and declared effective by the Securities and Exchange Commission (the "SEC") on August 12, 2026. The Offering is being made only by means of a prospectus forming part of the effective registration statement. A preliminary prospectus related to the offering was filed with the SEC on August 10, 2026. The final prospectus related to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the final prospectus relating to the offering, when available, may be obtained from: A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor,
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL). The Company's monotherapy and combination studies in acute myeloid leukemia (AML) are substantially complete, with additional funding the Company plans to continue development of emavusertib in AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene Discovery Technologies Limited, has the exclusive license to emavusertib (CA-4948).
Cautionary Note Regarding Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws, including without limitation, statements regarding the timing of the completion, and anticipated gross proceeds, of the offering, the use of proceeds for the offering and the terms of the common warrants and pre-funded warrants. Forward-looking statements may contain the words "believes," "expects," "anticipates," "plans," "intends," "seeks," "estimates," "assumes," "predicts," "projects," "targets," "will," "may," "would," "could," "should," "likelihood", "continue," "potential," "opportunity," "focus," "strategy," "mission," or similar expressions. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions. Other important factors that may cause or contribute to actual results being materially different from those indicated by forward-looking statements include the factors set forth under the captions "Risk Factor Summary" and "Risk Factors" in our most recent Annual Report on Form 10-K and the factors that are discussed in other filings that Curis periodically makes with the SEC. In addition, any forward-looking statements represent the views of Curis only as of the date of this press release and should not be relied upon as representing Curis's views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-inc-announces-pricing-of-5-6-million-public-offering-302850642.html
SOURCE Curis, Inc.